Sagimet Biosciences Series A Insider Trades
NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 9 · $4.62M
- Shares bought / sold
- 0 / 484.31K
- Net activity
- Net selling $4.6 million
Sagimet Biosciences Series A insider activity
Over the last 12 months, Sagimet Biosciences Series A insiders reported 17 transactions on SEC Form 4: 0 open-market purchases and 9 sales. Insiders bought $0 and sold $4.6 million worth of stock, for net insider selling of $4.6 million. The largest seller was Kemble George, with $3.9 million in reported sales.
The most recent filing shows Kemble George (Director) reporting a transaction in 326,618 shares at $6.36 on Aug 14, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put SGMT's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
SGMT insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 14, 2026 | Kemble GeorgeDirector | Sale | 350,987 | $3.59M | Form 4 |
| Aug 14, 2026 | Kemble GeorgeDirector | Option exercise | 24,369 | $154.99K | Form 4 |
| Aug 14, 2026 | Kemble GeorgeDirector | Option exercise | 326,618 | $2.08M | Form 4 |
| Aug 11, 2026 | Kemble GeorgeDirector | Sale | 20,206 | $201.15K | Form 4 |
| Aug 11, 2026 | Kemble GeorgeDirector | Option exercise | 10,455 | $66.49K | Form 4 |
| Aug 11, 2026 | Kemble GeorgeDirector | Option exercise | 9,751 | $62.02K | Form 4 |
| Jul 20, 2026 | Kemble GeorgeDirector | Sale | 18,844 | $140.53K | Form 4 |
| Jul 20, 2026 | Rozek ElizabethChief Legal & Admin. Officer | Sale | 10,545 | $81.83K | Form 4 |
| Jul 20, 2026 | Happel DavidPresident & CEO | Sale | 64,051 | $497.07K | Form 4 |
| Feb 19, 2026 | Chauche ThierryChief Financial Officer | Award | 44,000 | — | Form 4 |
| Feb 19, 2026 | Martins Eduardo BrunoChief Medical Officer | Award | 44,000 | — | Form 4 |
| Feb 19, 2026 | Happel DavidPresident & CEO | Award | 128,000 | — | Form 4 |
| Feb 19, 2026 | Rozek ElizabethChief Legal & Admin. Officer | Award | 44,000 | — | Form 4 |
| Feb 10, 2026 | Rozek ElizabethChief Legal & Admin. Officer | Sale | 2,622 | $14.05K | Form 4 |
| Feb 10, 2026 | Martins Eduardo BrunoChief Medical Officer | Sale | 3,640 | $19.51K | Form 4 |
| Feb 10, 2026 | Chauche ThierryChief Financial Officer | Sale | 1,312 | $7.03K | Form 4 |
| Feb 10, 2026 | Happel DavidPresident & CEO | Sale | 12,101 | $64.86K | Form 4 |
| Nov 20, 2025 | Kemble GeorgeExecutive Chairman | Sale | 37,688 | $289.98K | Form 4 |
| Nov 4, 2025 | Rozek ElizabethChief Legal & Admin. Officer | Award | 9,855 | — | Form 4 |
| Jul 21, 2025 | Happel DavidPresident & CEO | Sale | 65,478 | $598.12K | Form 4 |
| Jul 21, 2025 | Rozek ElizabethGeneral Counsel and CCO | Sale | 10,780 | $98.47K | Form 4 |
| Jul 21, 2025 | Martins Eduardo BrunoChief Medical Officer | Sale | 8,277 | $75.61K | Form 4 |
| Feb 6, 2025 | Rozek ElizabethGeneral Counsel and CCO | Award | 34,000 | — | Form 4 |
| Feb 6, 2025 | Happel DavidPresident & CEO | Award | 116,000 | — | Form 4 |
| Feb 6, 2025 | Chauche ThierryChief Financial Officer | Award | 17,000 | — | Form 4 |
| Feb 6, 2025 | Martins Eduardo BrunoChief Medical Officer | Award | 34,000 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4